Last reviewed · How we verify

NCT06863805

Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas

Recruiting now Last updated 7 March 2025
What this trial tests

trial testing 4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA in Thyroid Carcinoma in 10 participants. Currently enrolling.

Timeline
15 December 2022
Primary endpoint
31 December 2026
31 December 2027

Quick facts

Lead sponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment10
Start date15 December 2022
Primary completion31 December 2026
Estimated completion31 December 2027
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

18 and older, any sex, with Thyroid Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is aimed at all adult patients diagnosed with advanced thyroid carcinomas and well-differentiated thyroid carcinomas (DTC) iodine-refractory, well-differentiated iodine-refractory thyroid (RAI-R DTC) metastatic carcinomas that are candidates for systemic therapy. By simple blood sampling and analysis on peripheral blood of circulating DNA (ccf-DNA), circulating RNA (ccf-RNA), and counting and analysis of circulating tumor cells through the use of liquid biopsy, molecular profiling corresponding to those obtained by genomic sequencing on tumor tissue can be arrived at, depending on optimal therapeutic choices

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Thyroid Carcinoma

Currently open trials in the same condition.

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06863805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing